1246816-28-3
1246816-28-3
Chemical Structure
Acipimox-d4
Synonym(s): K-9321-d4
- CAS No.: 1246816-28-3
- Formula:C6H2D4N2O3
- Molecular Weight:158.15
IUPAC Name: 5-carboxy-2-(methyl-d3)pyrazine 1-oxide-6-d
InChIKey: DJQOOSBJCLSSEY-VYMTUXDUSA-N
SMILES: [2H]C(C1=CN=C(C(O)=O)C([2H])=[N+]1[O-])([2H])[2H]
Biological Activity: Acipimox-d4 is the deuterium labeled Acipimox. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox acutely inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Acipimox-d4 | Acipimox-d4 is the deuterium labeled Acipimox. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox acutely inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acipimox (Standard) | ≥98% | Acipimox (Standard) is the analytical standard of Acipimox. This product is intended for research and analytical applications. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acipimox-13C2,15N2 | Acipimox-13C2,15N2 (K-9321-13C2,15N2) is 13C- and 15N-labeled Acipimox (HY-B0283). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acipimox | 99.58% | Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
